Publications

Publications

Filter Results: (2) Arrow Down

Show Results For

NeuProtectRemove NeuProtect →

Page 1 of 2 Results

Are you looking for?

→Search All HBS Web
  • January 2014
  • Teaching Plan

MedImmune Ventures

By: Richard Hamermesh and Andrew Otazo
"MedImmune Ventures" highlights the problems faced by corporate venture capital firms, the challenges of investing in early-stage healthcare, and the difficulty of operating in distant markets. View Details
Keywords: MedImmune Ventures; NeuProtect; Corporate Venture Capital; Ron Laufer; Australia; Starfish Ventures; AstraZeneca; MEVE; Healthcare; Startup; Venture Capital; Business Startups; Health Industry; Australia; United States
Related
  • August 2013 (Revised October 2013)
  • Case

MedImmune Ventures

By: Richard G. Hamermesh and David Lane
Ron Laufer is the new Senior Managing Director of MedImmune Ventures, the corporate venture capital arm of AstraZeneca, a leading pharmaceuticals firm. Laufer has to decide whether to pursue a high-potential, but very risky, early-stage investment. The decision Laufer... View Details
Keywords: MedImmune; MedImmune Ventures; AstraZeneca; NeuProtect; Corporate Venturing; Biotechnology; Venture Investing; Venture Capital; Health Care and Treatment; Pharmaceutical Industry; Financial Services Industry; Biotechnology Industry; United States; Australia; Europe; London
Related

Are you looking for?

→Search All HBS Web